Treatment of dermatomyositis and polymyositis

Rheumatology

Volumn 41, Issue 1, 2002, Pages 7-13

  Choy, E H S ^a,c   Isenberg, D A ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLORAMBUCIL; COMPLEMENT COMPONENT C3B; CORTICOSTEROID; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FOLINIC ACID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE;

BONE NECROSIS; CANCER RISK; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DERMATOMYOSITIS; DISABILITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; IDIOPATHIC DISEASE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; MEDICAL SPECIALIST; MULTICENTER STUDY; NEUROLOGY; OSTEOPOROSIS; OUTCOMES RESEARCH; PLASMAPHERESIS; POLYMYOSITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOLOGY; SHORT COURSE THERAPY; VALIDATION PROCESS; WHOLE BODY RADIATION;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DERMATOMYOSITIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PLASMAPHERESIS; POLYMYOSITIS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0036099873     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (110)

1. Polymyositis and dermatomyositis (first of two parts)
2. Polymyositis and dermatomyositis (second of two parts)
3. Clinical, immunopathologic and therapeutic considerations of inflammatory myopathies
4. The treatment of inclusion body myositis: A retrospective review and a randomized, prospective trial of immunosuppressive therapy
5. Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine and methotrexate and a comparison of their efficacy
6. Incidence of polymyositis-dermatomyositis: A 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982
7. Epidemiology of polymyositis-dermatomyositis in Israel, 1960-76
8. Occurrence of polymyositis in the county of Gavleborg, Sweden
9. The incidence of juvenile dermatomyositis: Results from a nation-wide study
10. Dermatomyositis in the Transvaal and its occurrence in the Bantu
11. The epidemiology of polymyositis
12. Polymyositis and dermatomyositis in children: An epidemiologic and clinical comparative analysis
13. Polymyositis: A survey of 89 cases with particular reference to treatment and prognosis
14. Epidemiologic features of diffuse connective tissue disorders in Rochester, Minn., 1951 through 1967, with special reference to systemic lupus erythematosus
15. Adult onset polymyositis/dermatomyositis: Clinical and laboratory features and treatment response in 75 patients
16. Prevalence studies of multiple sclerosis, myasthenia gravis and myopathies in Kumamoto district, Japan
17. Dermatomyositis with a report of case which presented a rare muscle anomaly but once described in man
18. Treatment of idiopathic inflammatory myopathies in a retrospective analysis if 63 Caucasian patients longitudinally followed at a single centre
19. Prognosis in adult polymyositis
20. Survival in polymyositis: Corticosteroids and risk factors
21. Mortality from polymyositis and dermatomyositis in the United States, 1968-1978
22. Biopsy proven polymyositis in Victoria 1982-1987: Analysis of prognostic factors
23. Long-term prognosis of 69 patients with dermatomyositis or polymyositis
24. Course of dermatomyositis-polymyositis: Comparison of untreated and cortisone-treated patients
25. Factors affecting survivorship in polymyositis. A life-table study of 124 patients
26. Prognostic factors in polymyositis/dermatomyositis. A computer-assisted analysis of ninety-two cases
27. Polymyositis-treatment and prognosis. A study of 107 patients
28. Dermatopolymyositis and other connective tissue diseases: A review of 105 cases
29. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis
30. Polymyositis: Its presentation, morbidity and mortality
31. Idiopathic myositis-A rheumatological review
32. A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis
33. Current treatment of the inflammatory myopathies
34. Management of polymyositis and dermatomyositis
35. Treatment of inflammatory myopathies
36. Therapy for myositis
37. Drug therapy in juvenile dermatomyositis: Follow-up study
38. Polymyositis/dermatomyositis: Clinical features and outcome in 22 patients
39. Functional outcome of myositis patients: Can a low-dose glucocorticoid regimen achieve good functional results?
40. Update on therapy for refractory dermatomyositis and polymyositis
41. Successful treatment of refractory polymyositis with pulse intravenous cyclophosphamide and low-dose weekly oral methotrexate therapy
42. Pulsed intravenous methylprednisolone therapy for inflammatory myopathies: Evaluation of the effect by comparing two consecutive biopsies from the same muscle
43. Treatment of refractory myositis: A randomized crossover study of two new cytotoxic regimens
44. Adult-onset polymyositis-dermatomyositis: Description of 25 patients with emphasis on treatment
45. Prednisone and Azathioprine for polymyositis: Long-term followup
46. Azathioprine with prednisone for polymyositis. A controlled, clinical trial
47. The value of methotrexate in dermatomyositis
48. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis
49. Polymyositis and chronic graft-versus-host disease: Efficacy of intravenous gammaglobulin and methotrexate
50. Treatment of dermatomyositis with methotrexate
51. Methotrexate for polymyositis associated with primary biliary cirrhosis
52. Methotrexate treatment of recalcitrant childhood dermatomyositis
53. Coexistence of adult onset Still's disease and polymyositis with rhabdomyolysis successfully treated with methotrexate and corticosteroids
54. Childhood dermatomyositis and polymyositis. Treatment with methotrexate and prednisone
55. Methotrexate treatment in dermatomyositis
56. Combined use of cyclosporine A and methotrexate in refractory polymyositis
57. Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis
58. Treatment of corticosteroid-resistant polymyositis with methotrexate
59. Methotrexate therapy in polymyositis
60. Polymyositis and dermatomyositis: Combined methotrexate and corticosteroid therapy
61. Treatment of dermatomyositis with methotrexate and prednisone
62. Treatment of dermatomyositis with methotrexate
63. Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis
64. Cyclosporine treatment for polymyositis/dermatomyositis: Is it possible to rescue the deteriorating cases with interstitial pneumonitis?
65. Cyclosporin A therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases
66. Dermatomyositis: Remission induced with combined oral cyclosporine and high-dose intravenous immune globulin
67. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis. Results of a preliminary study
68. Immunointervention with cyclosporin A in autoimmune neurological disorders
69. Cyclosporin in the management of polymyositis and dermatomyositis
70. Clinical effects of cyclosporin in dermatomyositis
71. The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy
72. Treatment of idiopathic inflammatory myopathies with cyclophosphamide pulses: Clinical experience and a review of the literature
73. Polymyositis-dermatomyositis: 25 years of follow-up of 50 patients disease course, treatment, prognostic factors
74. Successful IV pulse cyclophosphamide in refractory PM in 3 patients with SLE
75. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis
76. Cyclophosphamide in severe polymyositis
77. Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis
78. Prognosis and treatment of polymyositis with particular reference to steroid resistant patients
79. Chlorambucil. An effective corticosteroid-sparing agent for patients with recalcitrant dermatomyositis
80. Treatment of polymyositis and dermatomyositis
81. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses
82. Cyclosporin for polymyositis
83. Cyclosporin A in adult dermatomyositis
84. A case of adult dermatomyositis treated with cyclosporin A
85. Cyclosporin A treatment of dermatomyositis
86. Dermatomyositis treated with cyclosporin
87. Polymyositis and cyclosporin A
88. Cyclosporin for dermatomyositis
89. Severe dermatomyositis treated with cyclosporin A
90. Cyclosporin for polymyositis
91. Cyclosporin for acute dermatomyositis
92. Combination immunosuppressive treatment of steroid-resistant dermatomyositis/polymyositis
93. The use of intravenous immune globulin in collagen vascular disorders: A potentially new modality of therapy
94. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: An open study with 20 adult patients
95. Treatment of dermatomyositis with intravenous gammaglobulin
96. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis
97. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments
98. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: An open study in 11 adult patients
99. Intravenous immunoglobulin in juvenile dermatomyositis-four year review of nine cases
100. Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin
101. Plasmapheresis in idiopathic inflammatory myopathy. Experience with 35 patients
102. Plasma exchange in dermatomyositis/polymyositis: Beneficial effects in three cases
103. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis
104. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis
105. Polymyositis, remarkable response to total body irradiation
106. Response to total body irradiation dermatomyositis
107. Total body irradiation and the cause of polymyositis
108. Adult polymyositis and dermatomyositis
109. Improvement of physical fitness and muscle strength in polymyositis/dermatomyositis patients by a training programme
110. Polymyositis and dermatomyositis